Trial · NCT05174065
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 16 | Placebo-controlled Period: Placebo | 35.3 | 95% Confidence Interval 25.3 to 45.4 | percentage of participants | |
| Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at Week 16 | Placebo-controlled Period: Apremilast | 67.8 | 95% Confidence Interval 57.9 to 77.6 | percentage of participants | |
| Change From Baseline in PPPASI Total Score at Week 16 | Placebo-controlled Period: Placebo | -5.98 | Standard Error 0.999 | score on a scale | |
| Change From Baseline in PPPASI Total Score at Week 16 | Placebo-controlled Period: Apremilast | -12.12 | Standard Error 1.002 | score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Severity Index (PPSI) Total Score at Week 16 | Placebo-controlled Period: Placebo | -1.9 | Standard Error 0.24 | score on a scale | |
| Change From Baseline in Palmoplantar Pustulosis Severity Index (PPSI) Total Score at Week 16 | Placebo-controlled Period: Apremilast | -3.4 | Standard Error 0.24 | score on a scale | |
| Change From Baseline in Visual Analogue Scale (VAS) Assessment for PPP Symptoms (Pruritus) at Week 16 | Placebo-controlled Period: Placebo | -9.9 | Standard Error 2.68 | score on a scale | |
| Change From Baseline in Visual Analogue Scale (VAS) Assessment for PPP Symptoms (Pruritus) at Week 16 | Placebo-controlled Period: Apremilast | -17.6 | Standard Error 2.67 | score on a scale | |
| Change From Baseline in VAS Assessment for PPP Symptoms (Pain/Discomfort) at Week 16 | Placebo-controlled Period: Placebo | -7.5 | Standard Error 2.97 | score on a scale | |
| Change From Baseline in VAS Assessment for PPP Symptoms (Pain/Discomfort) at Week 16 | Placebo-controlled Period: Apremilast | -18.3 | Standard Error 2.96 | score on a scale | |
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16 | Placebo-controlled Period: Placebo | -0.8 | Standard Error 0.37 | score on a scale | |
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16 | Placebo-controlled Period: Apremilast | -2.3 | Standard Error 0.37 | score on a scale | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Placebo-controlled Period: Placebo | Any TEAEs | 43 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Placebo-controlled Period: Apremilast | Any TEAEs | 63 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Apremilast Exposure Period: Apremilast | Any TEAEs | 148 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Placebo-controlled Period: Placebo | Serious TEAEs | 1 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Placebo-controlled Period: Apremilast | Serious TEAEs | 1 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Apremilast Exposure Period: Apremilast | Serious TEAEs | 9 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Placebo-controlled Period: Placebo | TEAEs of Interest | 3 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Placebo-controlled Period: Apremilast | TEAEs of Interest | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05174065/results